S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
NASDAQ:ADMA

ADMA Biologics - ADMA Stock Forecast, Price & News

$3.69
+0.09 (+2.50%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.62
$3.71
50-Day Range
$3.16
$3.88
52-Week Range
$1.36
$3.98
Volume
2.08 million shs
Average Volume
2.60 million shs
Market Capitalization
$726.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

ADMA Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.3% Upside
$5.25 Price Target
Short Interest
Healthy
6.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of ADMA Biologics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$62,851 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.30) to ($0.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

233rd out of 1,055 stocks

Biological Products, Except Diagnostic Industry

38th out of 170 stocks


ADMA stock logo

About ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
ADMA Biologics gains as guidance exceeds consensus
ADMA Biologics: FY22 Numbers Key Inflection Point
ADMA.O - | Stock Price & Latest News | Reuters
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
H.C. Wainwright Keeps Their Buy Rating on ADMA Biologics (ADMA)
Biotech Penny Stocks That Delivered Impressive Gains In 2022
ADMA Biologics hits 52-week high after strong Q3 beat
A Preview Of ADMA Biologics's Earnings
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Company Calendar

Last Earnings
11/09/2022
Today
1/31/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMA
Employees
527
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.25
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+42.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-71,650,000.00
Pretax Margin
-53.90%

Debt

Sales & Book Value

Annual Sales
$80.94 million
Book Value
$0.72 per share

Miscellaneous

Free Float
185,167,000
Market Cap
$726.12 million
Optionable
Optionable
Beta
0.92

Key Executives

  • Adam S. GrossmanAdam S. Grossman
    President, Chief Executive Officer & Director
  • Atkinson Vernon
    Operations Director
  • Brian LenzBrian Lenz
    Chief Financial Officer & Executive Vice President
  • Kaitlin Kestenberg
    Vice President-Compliance & Clinical Operations
  • Lucy DeMario
    Senior Director-Scientific & Data Analysis













ADMA Stock - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings
or view top-rated stocks.

What is ADMA Biologics' stock price forecast for 2023?

2 brokers have issued 12-month target prices for ADMA Biologics' stock. Their ADMA share price forecasts range from $4.50 to $6.00. On average, they expect the company's share price to reach $5.25 in the next year. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for ADMA
or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2023?

ADMA Biologics' stock was trading at $3.88 at the start of the year. Since then, ADMA shares have decreased by 4.9% and is now trading at $3.69.
View the best growth stocks for 2023 here
.

Are investors shorting ADMA Biologics?

ADMA Biologics saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 12,050,000 shares, a decrease of 5.3% from the December 31st total of 12,720,000 shares. Based on an average trading volume of 3,290,000 shares, the short-interest ratio is currently 3.7 days.
View ADMA Biologics' Short Interest
.

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ADMA earnings forecast
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The biotechnology company had revenue of $41.09 million for the quarter, compared to analyst estimates of $34.57 million. ADMA Biologics had a negative trailing twelve-month return on equity of 52.73% and a negative net margin of 53.89%.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics updated its FY 2022 earnings guidance on Saturday, January, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $153.00 million-$154.00 million, compared to the consensus revenue estimate of $148.95 million.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.20%), First Hawaiian Bank (0.10%), AE Wealth Management LLC (0.01%), Verdence Capital Advisors LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends
.

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $3.69.

How much money does ADMA Biologics make?

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $726.12 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does ADMA Biologics have?

The company employs 527 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.

This page (NASDAQ:ADMA) was last updated on 2/1/2023 by MarketBeat.com Staff